Truist Securities Maintains Buy on Nuvation Bio, Raises Price Target to $13
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $12 to $13.
Truist Securities analyst Gregory Renza maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $12 to $13.